Diabetes patient gets Israel’s highest-ever award in Avandia class-action.

Israeli newspaper Ha’aretz (7/2, Ben) reported that, “The highest-ever award in an Israeli class-action suit against a drug manufacturer – NIS 12.1 million – was recently made under a compromise agreement reached between a diabetes patient and GlaxoSmithKline, the maker of Avandia. The suit had been filed by a diabetic who claimed that GSK had concealed data from the public that showed the drug, which is used to treat people with type-2 diabetes, increased the risk of dying from a heart attack.”